copanlisib (aliqopa) Report issue

Small molecule Orphan Drug FDA Approved FDA First in Class Fast Track FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

  • Now
Copanlisib, developed by Bayer, is a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents. Copanlisib is currently under Phase II/III clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia.   NCATS

  • SMILES: Cl.Cl.COc1c(OCCCN2CCOCC2)ccc3C4=NCCN4C(=Nc13)NC(=O)c5cnc(N)nc5
  • Mol. Mass: 553.45
  • ALogP: 0.66
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)

United States

$3474.8500 - $4618.6300
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

2-amino-n-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo(1,2-c)quinazolin-4-yl)pyrimidine-5-carboxamide | aliqopa | bay 80-6946 | bay-80-6946 | copanlisib | copanlisib dihydrochloride


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue